We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Clinical Microarray System Developed for Genetic Analysis Screening

By LabMedica International staff writers
Posted on 02 Jan 2023

In precision medicine, preoperative or postoperative genetic testing can be used to stratify patients according to disease states and select appropriate drugs, enabling efficient delivery of personalized treatment. More...

Postoperative monitoring can also be used to predict the possibility of recurrence and other prognostic factors. With the advancement of liquid biopsy genetic testing, preventive medicine is expected to have an impact in the future in terms of estimating the risk of morbidity and preventing diseases.

Clinical Scientists at the Yamaguchi University Graduate School of Medicine (Ube, Japan) and their colleagues at Toyo Kohan Co., Ltd (Shinagawa, Tokyo, Japan) developed a novel microarray-based genetic analysis system that uses a Peltier element to overcome the issues of conventional microarrays, such as the long measurement time and high cost. They constructed a microarray system to detect the UDP-glucuronosyltransferase gene polymorphisms UGT1A1*6 and UGT1A1*28 in patients eligible for irinotecan hydrochloride treatment for use in clinical laboratories. Irinotecan hydrochloride is used to treat cancer.

Threshold values were set based on the mean and standard deviation of genotype determination values for each genotype calculated from 22 human specimens. Then, genotype determination values were calculated using the developed genetic analyzer for 111 human specimens that had already been examined using the existing Invader UGT1A1 Molecular Assay (Sekisui Medical, Tokyo, Japan), and the genotypes were determined based on the genotype determination thresholds that were set. Amplification was performed on a Mastercycler Pro S PCR system (Eppendorf, Hamburg, Germany).

The investigators reported that the hybridization temperature reached its target in 1/27th of the time required by the conventional system. They assessed 111 human clinical samples and found that their results agreed with those obtained using existing methods. The total time for the newly developed device was reduced by 85 minutes compared to that for existing methods, as the automated DNA microarray eliminates the time that existing methods spend on manual operation.

The authors concluded that a microarray system suitable for clinical use was developed using a surface treatment that enables high-density and strong DNA fixation. Using the assay system for the UGT1A1*28 and UGT1A1*6 polymorphisms, the optimal hybridization temperature and thresholds for genotype determination were set. In a performance evaluation using 111 samples, the results of the present device were comparable to those of an existing assay. Therefore, they proposed that the system developed in their study is suitable for genetic testing in clinical laboratories. The study was published on December 26, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Yamaguchi University Graduate School of Medicine
Toyo Kohan Co., Ltd
Sekisui Medical 
Eppendorf 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.